Shopping Cart
- Remove All
- Your shopping cart is currently empty
ALV2 is a potent and selective Helios degrader that binds to CRBN protein, with an IC50 of 0.57 μM. Helios, a zinc-finger transcription factor, is essential for maintaining a stable T reg cell phenotype in the inflammatory tumor microenvironment.
Description | ALV2 is a potent and selective Helios degrader that binds to CRBN protein, with an IC50 of 0.57 μM. Helios, a zinc-finger transcription factor, is essential for maintaining a stable T reg cell phenotype in the inflammatory tumor microenvironment. |
Targets&IC50 | CRBN:0.57 μM (IC50) |
In vitro | ALV2, within a concentration range of 10 nM to 100 μM, initiates CRBN-Helios dimerization as evidenced by the TR-FRET assay[1]. At lower concentrations (0.1-10 μM), ALV2 specifically facilitates the degradation of Helios in Jurkat cells[1]. Moreover, when pre-administered for 18 hours at a concentration of 1 μM, ALV2 enhances IL-2 secretion in Jurkat cells[1]. |
In vivo | ALV2, administered intraperitoneally at a dosage of 100 mg/kg twice daily for 7 days, selectively induces Helios degradation in vivo in Crbn I391V/I391V mouse models. This treatment specifically reduced Helios levels without affecting Ikaros in splenic CD4 + FoxP3 + T regulatory cells. |
Molecular Weight | 523.97 |
Formula | C26H26ClN5O5 |
Cas No. | 2438124-95-7 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.